Gland Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2023.
In this week so far, the stock rallied over 5%. After a long consolidation, eventually the stock cleared the short-term resistance of 129 and formed a bullish candle on weekly charts, which is largely positive.
This article delves into the significance of RSI in assessing stock movements, particularly in overbought stocks. Examining 16 stocks that experienced bearish or declining RSI while being in the overbought zone, ETMarkets highlights 10 stocks as potential case studies.
Global brokerage firm Jefferies upgraded Gland Pharma s stock to buy from underperform with an increased price target of Rs 1,640 from Rs 1,065 earlier. Bernstein also gave an outperform rating on Gland Pharma, saying that the Q1 numbers point towards early signs of revival in base business.